Latest news articles

Added 3 days ago Drug news

Phase III study of Crysvita demonstrates superiority in X-linked hypophosphatemia.- Ultragenyx Pharma + Kyowa Hakko Kirin

Ultragenyx Pharmaceutical, Kyowa Hakko Kirin, and Kyowa Kirin International announced positive results of a 64-week efficacy and safety analysis of...

Added 20 days ago Drug news

Phase III success for Ultomiris in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome . Alexion Pharma

Alexion Pharmaceuticals, Inc. announced that the Phase III study of Ultomiris (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its...

Added 1 month ago Drug news

Positive results from three phase III studies of roxadustat for anemia in patients with chronic kidney disease. FibroGen + AstraZeneca

FibroGen, Inc. announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI), met all primary efficacy endpoints in...

Search all news articles for Deficiency and other anaemia
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Load more

Guidelines

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Anaemia and iron deficiency are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents.

Added 10 months ago

Guidelines for the diagnosis and management of adult aplastic anaemia

This is a comprehensive but pragmatic new guideline and focuses on the accurate diagnosis, delineation of severity types and subsequent management of this rare haematological condition.

Added 3 years ago

The diagnosis and management of primary autoimmune haemolytic anaemia

The objective of this guideline is to provide healthcare professionals with guidance on the management of patients with primary autoimmune haemolytic anaemia (AIHA).

Added 11 months ago

Search all guidelines for Deficiency and other anaemia
 

Journal articles

Causal relationship between hypoalbuminemia and acute kidney injury.

Our meta-analysis published in 2010 provided evidence that low levels of serum albumin (hypoalbuminemia) are a significant independent predictor of acute kidney injury (AKI) and death following AKI.

Added 1 year ago

Could testosterone therapy in hypogonadal men ameliorate anemia, a cardiovascular risk factor? An observational, 54-week cumulative registry study.

In this study we investigated if testosterone undecanoate attenuates anemia and the risk of cardiovascular disease in patients with hypogonadism.

Added 1 year ago

Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab.

Hemolytic-uremic syndrome (HUS) is the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury (AKI); the main cause of multi-organ failure is related to thrombotic microangiopathy (TMA).

Added 1 year ago

Search all journal articles for Deficiency and other anaemia
 

Clinical trials

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (BELIEVE)

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in...

Added 7 months ago

A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease

This is a Phase 1/2, open label, safety, and efficacy study of the administration of LentiGlobin BB305 Drug Product to subjects with either beta-thalassemia major or severe sickle cell disease (SCD).

Added 5 years ago

Search all clinical trials for Deficiency and other anaemia
 

CME

Facial conditions: illustrated

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0
Search all CME for Deficiency and other anaemia